Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab.
D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015463:Leukemia, Prolymphocytic / Q000188:drug therapy; D015458:Leukemia, T-Cell / Q000188:drug therapy; D009894:Opportunistic Infections / Q000150:complications*; D010322:Parvoviridae Infections / Q000150:complications*; D016732:Parvovirus B19, Human; D012010:Red-Cell Aplasia, Pure / Q000821:virology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab